Quoin Pharmaceuticals Ltd. (QNRX) - 10-Q Summary
Business Context and Reporting Period
Company: Quoin Pharmaceuticals Ltd.
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Model: Late-stage clinical specialty pharmaceutical company focused on rare and orphan diseases. The company has no commercialized products and generates no revenue.
Key Asset: Lead product QRX003, a topical lotion for Netherton Syndrome (NS), currently in two pivotal registrational clinical studies. The company also holds options for QRX008 (scleroderma) and is developing topical rapamycin formulations.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,948,165) | $(2,349,885) | $(11,456,282) | $(6,651,198) |
| Loss per ADS (Basic/Diluted) | $(6.71) | $(16.29) | $(19.50) | $(57.18) |
| Operating Expenses | $4,019,925 | $2,528,002 | $11,770,281 | $7,123,404 |
| Cash & Cash Equivalents (Sep 30, 2025) | $1,830,906 | |||
| Investments (Sep 30, 2025) | $3,581,772 | |||
| Total Current Liabilities | $5,764,551 | |||
| Accumulated Deficit | $(66,622,074) |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the nine months ended September 30, 2025, increased by approximately $4.8 million (72%) compared to the same period in 2024, driven primarily by a $4.15 million increase in Research and Development (R&D) expenses.
- R&D Acceleration: R&D expenses rose 163% year-over-year for the nine-month period, largely due to increased external expenditures ($4.0 million) for clinical studies of QRX003.
- Share Structure: Effective April 9, 2025, the company executed a 1-for-35 reverse split of its American Depositary Shares (ADSs) to regain compliance with Nasdaq minimum bid price requirements.
- Equity Position: As of September 30, 2025, the company reported a shareholders' deficit of approximately $1.2 million, down from positive equity of $9.2 million at year-end 2024.
Guidance, Outlook, and Risks
- Recent Financing (Subsequent Event): On October 14, 2025, the company closed a private placement raising approximately $16.6 million in gross proceeds (net proceeds ~$15 million). Additionally, $3.3 million was received from the exercise of warrants issued in December 2024.
- Liquidity Outlook: Management states that following the October 2025 financing, the company has sufficient resources to fund operations for at least one year from the filing date.
- Regulatory Milestone: On October 21, 2025, the FDA granted Orphan Drug Designation to QRX003 for Netherton Syndrome, following a similar designation by the EMA in May 2025.
- Nasdaq Compliance Risk: While the company regained compliance with the minimum bid price requirement via the reverse split, it remains below the $2.5 million stockholders' equity requirement for Nasdaq listing. Failure to maintain compliance could result in delisting.
- Government Shutdown Risk: The filing notes potential disruptions to FDA review processes due to the U.S. federal government shutdown that began September 30, 2025.
Investor Verification Checklist
- Capital Runway: Verify the actual cash balance post-closing of the October 2025 private placement and confirm the timeline for the next anticipated capital raise.
- Nasdaq Status: Monitor the company's progress in meeting the $2.5 million stockholders' equity requirement to avoid delisting.
- Clinical Trial Progress: Review upcoming data readouts for the pivotal QRX003 trials for Netherton Syndrome, as these are critical for future valuation and funding.
- Related Party Debt: Note the significant amounts due to officers ($2.47 million total, with $1.87 million classified as long-term) and the repayment schedule.
- Warrant Dilution: Assess the potential dilution from the new Series H, I, J, and K warrants issued in the October 2025 offering, which have exercise prices ranging from $9.075 to $12.375.